ATN 026 Antiretroviral Medications [CRF 8] Dataset in Evaluation of HIV-Specific CD8+ T-Cell Responses and Escape Mutations as Explanations for the Observed Differences in Disease Progression Conferred by HLA Class I Alleles

Data from Antiretroviral Medications Form [CRF 8]
Study Description
ATN 026 investigated the association between HLA class I genotypes and differing HIV-1 disease progression. The study assessed HIV-1 specific CD8+ T-cell responses and the dominant HIV-1 genotype among individuals identified as HLA-B*27, B*35, B*53, and B*57 positive. Participants were followed for two years with medical history, physical exam, and blood sample collection performed every six months. All participants were previously enrolled in REACH, a 5-year longitudinal adolescent study. Some biospecimens are available; for inquiries, please contact Dr. Paul Goepfert ([e-mail]). Former REACH study participants identified as HLA Class I HLA-B*27, B*35, B*53, and/or B*57 positive

抗逆转录病毒药物表单[CRF 8]相关数据
研究概况
ATN 026研究探讨了人类白细胞抗原（Human Leukocyte Antigen，HLA）I类基因型与不同人类免疫缺陷病毒1型（HIV-1）疾病进展进程之间的关联。该研究针对经鉴定为HLA-B*27、B*35、B*53及B*57阳性的个体，评估了HIV-1特异性CD8+ T细胞应答以及该群体中的优势HIV-1基因型。研究对象被随访两年，每六个月采集一次病史、开展体格检查并收集血液样本。所有研究对象此前均参与了REACH这项为期5年的青少年纵向队列研究。本数据集包含部分生物样本；若有咨询需求，请联系Paul Goepfert博士（邮箱：[e-mail]）。本数据集的受试者为此前参与REACH研究且被鉴定为HLA I类相关HLA-B*27、B*35、B*53及/或B*57阳性的参与者。